BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 33906820)

  • 1. Tumor resident regulatory T cells.
    Glasner A; Plitas G
    Semin Immunol; 2021 Feb; 52():101476. PubMed ID: 33906820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
    Aristin Revilla S; Kranenburg O; Coffer PJ
    Front Immunol; 2022; 13():903564. PubMed ID: 35874729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.
    Whiteside TL
    Expert Opin Ther Targets; 2018 Apr; 22(4):353-363. PubMed ID: 29532697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of CD4
    Hariyanto AD; Permata TBM; Gondhowiardjo SA
    Immunol Med; 2022 Jun; 45(2):94-107. PubMed ID: 34495808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reprogramming of Treg cells in the inflammatory microenvironment during immunotherapy: a literature review.
    Wu X; Zhou Z; Cao Q; Chen Y; Gong J; Zhang Q; Qiang Y; Lu Y; Cao G
    Front Immunol; 2023; 14():1268188. PubMed ID: 37753092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity.
    Kalim KW; Yang JQ; Wunderlich M; Modur V; Nguyen P; Li Y; Wen T; Davis AK; Verma R; Lu QR; Jegga AG; Zheng Y; Guo F
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36427906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting post-translational modifications of Foxp3: a new paradigm for regulatory T cell-specific therapy.
    Riaz F; Huang Z; Pan F
    Front Immunol; 2023; 14():1280741. PubMed ID: 37936703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Treg cells in cancer immunotherapy.
    Tanaka A; Sakaguchi S
    Eur J Immunol; 2019 Aug; 49(8):1140-1146. PubMed ID: 31257581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?
    Liu J; Zhang B; Zhang G; Shang D
    Front Immunol; 2024; 15():1345838. PubMed ID: 38449875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
    Kumar P; Saini S; Prabhakar BS
    Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
    Overacre-Delgoffe AE; Vignali DAA
    Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.
    Yano H; Andrews LP; Workman CJ; Vignali DAA
    Immunology; 2019 Jul; 157(3):232-247. PubMed ID: 31087644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
    Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
    Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of regulatory T cells in cancer immunology and immunotherapy.
    Sugiyama D; Hinohara K; Nishikawa H
    Exp Dermatol; 2023 Mar; 32(3):256-263. PubMed ID: 36458459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunometabolism of regulatory T cells in cancer.
    Galgani M; Bruzzaniti S; La Rocca C; Micillo T; de Candia P; Bifulco M; Matarese G
    Mol Aspects Med; 2021 Feb; 77():100936. PubMed ID: 33250195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
    Nishikawa H; Koyama S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-coding RNA in tumor-infiltrating regulatory T cells formation and associated immunotherapy.
    Ma Y; Xu X; Wang H; Liu Y; Piao H
    Front Immunol; 2023; 14():1228331. PubMed ID: 37671150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells.
    Satoh K; Kobayashi Y; Fujimaki K; Hayashi S; Ishida S; Sugiyama D; Sato T; Lim K; Miyamoto M; Kozuma S; Kadokura M; Wakita K; Hata M; Hirahara K; Amano M; Watanabe I; Okamoto A; Tuettenberg A; Jonuleit H; Tanemura A; Maruyama S; Agatsuma T; Wada T; Nishikawa H
    Int Immunol; 2021 Jul; 33(8):435-446. PubMed ID: 34235533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.